Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA)

Regeneron Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Nonproliferative Diabetic Retinopathy

Treatments: Drug: Sham; Drug: Intravitreal aflibercept injection [IAI]

Study type: Interventional

Funder types: Industry

Identifiers

NCT02718326

2016-002639-14 (EudraCT Number)

VGFTe-OD-1411

Details and patient eligibility

About

The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).

The secondary objectives of the study are:

• To characterize the safety of IVT aflibercept in patients with moderately severe to severe NPDR
• To determine if IVT aflibercept will prevent the worsening of diabetic retinopathy and reduce the incidence of DME
• To determine the anatomic effects of IVT aflibercept in patients with moderately severe to severe NPDR

Enrollment: 402 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

1. Men or women ≥18 years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe nonproliferative diabetic retinopathy (NPDR) [(diabetic retinopathy severity scale (DRSS) levels 47 or 53)], confirmed by the central reading center, in whom panretinal photocoagulation (PRP) can be safely deferred for at least 6 months per the investigator
2. Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)

Key Exclusion Criteria:

1. Presence of diabetic macular edema (DME) threatening the center of the macula in the study eye
2. Evidence of retinal neovascularization on clinical examination or Fluorescein Angiography (FA)
3. Any prior focal or grid laser photocoagulation or any prior PRP in the study eye
4. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment or intravitreal (IVT) anti-VEGF treatment in the study eye
5. Any prior intraocular steroid injection in the study eye
6. Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional retinal detachment visible at the screening assessments in the study eye

Note: Other inclusion/ exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

402 participants in 3 patient groups

Dosing regimen 1

Experimental group

Description:

Participants will receive IVT aflibercept dosing regimen 1

Treatment:

Drug: Intravitreal aflibercept injection [IAI]

Dosing regimen 2

Experimental group

Description:

Participants will receive IVT aflibercept dosing regimen 2

Treatment:

Drug: Intravitreal aflibercept injection [IAI]

Dosing regimen 3

Sham Comparator group

Description:

Participants will receive matching sham injections

Treatment:

Drug: Sham